Catalyst Pharmaceutical Clinical Trial Misses Mark, Stock Plummets

Published December 5, 2012

Catalyst Pharmaceutical clinical trial misses mark, stock plummets
Filed under: cocaine treatment clinical trials
Shares of Catalyst Pharmaceutical Partners fell as much as 64 percent in pre-market trading Thursday after it announced that its clinical trial for a drug to treat cocaine addiction failed to meet its goal. The Coral Gables-based company (NASDAQ: CPRX) … Read more on L.A. Biz